Specifically, there have been several reports in which patients with hematological malignancies responded DLI to treat recurrent disease following HCT and coincident emergence of HA-1-specific T cells in vivo was documented using peptide/HLA tetramer analysis and/or isolation of the HA-1-specific T cells from the peripheral blood (29, 51, 71–73). The gene discussed is ARHGAP45; the disease is hematologic disorder.